BioSpace News Archive

Drug Development

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Syros Pharmaceuticals today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist.

December 6, 2023
·
8 min read
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Diabetes, demonstrating that AIM2 and NLRP3 inflammasome activation contributes to development of atherosclerosis in two different animal models of type 1 diabetes.

December 6, 2023
·
6 min read
Drug Development

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

Century Therapeutics today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101.

December 6, 2023
·
9 min read
Deals

Danaher Completes Acquisition of Abcam

Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”).

December 6, 2023
·
1 min read
Drug Development

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Cidara Therapeutics, Inc. today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis.

December 6, 2023
·
4 min read
BioForest

Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference

Avalyn Pharma Inc. today announced that it will participate in the 2023 RBC Capital Markets Healthcare Private Company Conference, being held virtually December 13-14, 2023.

December 6, 2023
·
1 min read
Biotech Beach

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays.

December 6, 2023
·
5 min read
Biotech Beach

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

BioAtla, Inc. today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 10:00 AM ET.

December 6, 2023
·
8 min read
Drug Development

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Organovo Holdings, Inc. today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024.

December 6, 2023
·
4 min read
Business

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Matthew Maurer, M.D. as Chief Medical Officer.

December 6, 2023
·
4 min read